SIM
SYRE icon

Spark Investment Management’s Spyre Therapeutics SYRE Stock Holding History

Spark Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-760
Closed -$188K – 720
2018
Q1 		$188K Buy
760
+312
+70% +$56.4K 0.01% 513
2017
Q4 		$60K Sell
448
-1,232
-73% -$151K ﹤0.01% 653
2017
Q3 		$207K Buy
1,680
+1,112
+196% +$104K 0.01% 603
2017
Q2 		$54K Buy
+568
New +$78.5K ﹤0.01% 742
2017
Q1 		– Sell
-480
Closed -$52K – 888
2016
Q4 		$52K Buy
+480
New +$70K ﹤0.01% 741

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Spark Investment Management's SYRE Position: Q2 2018 in Review

Spark Investment Management sold out of Spyre Therapeutics (SYRE) in Q2 2018, closing a stake of 760 shares — an estimated $188K sold.

Spark Investment Management first reported a position in SYRE in Q4 2016 and held it in 5 quarters. The position peaked at $207K in Q3 2017. 64 funds tracked by Wall St. Rank hold SYRE as of Q2 2018.

  • Spark Investment Management reported no remaining Spyre Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Spark Investment Management sold 760 Spyre Therapeutics shares in Q2 2018, an estimated $188K.
  • Spark Investment Management first reported a position in Spyre Therapeutics in Q4 2016 and held it in 5 quarters.
  • Spark Investment Management's Spyre Therapeutics position peaked at $207K in Q3 2017.
  • 64 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2018.

Based on Spark Investment Management's 13F filing for Q2 2018, filed 8 Aug 2018.